Clinical Trials Directory

Trials / Completed

CompletedNCT01824771

Effects of Continuous Veno-venous Haemofiltration on Plasma Lactate in Critically Ill Patients

Status
Completed
Phase
Study type
Observational
Enrollment
15 (actual)
Sponsor
First Affiliated Hospital, Sun Yat-Sen University · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

Continuous Veno-Venous Hemofiltration (CVVH) can eliminate metabolic products effectively and replace renal function partly. It is widely used in intensive care units (ICUs), especially for patients with acute kidney injury/failure in an unstable hemodynamic status. Lactate is a molecule smaller than glucose, which can pass through filtration membrane freely in CVVH. Therefore, the blood lactate concentrations would no longer reflect tissue oxygenation status in patients with unstable hemodynamic status. However, there is no prospective study evaluated the effect of CVVH on lactate removal in critically ill patients. The influence of different dose of CVVH on lactate elimination is not clear in patients with different level of serum lactate. Our study aimed to find out how the dose of CVVH effects on lactate clearance, and then re-estimate the prognostic value of lactate in critically ill patients with CVVH.

Conditions

Interventions

TypeNameDescription
OTHERPlasma lactate were measuredThree different doses (20 ml/kg/h, 35 ml/kg/h and 45 ml/kg/h) of CVVH were applied to critically ill patients who experiencing CVVH. Each dose of CVVH was sequentially gave to each patient and lasted for 30 minutes separately

Timeline

Start date
2013-03-03
Primary completion
2015-03-03
Completion
2015-03-20
First posted
2013-04-05
Last updated
2022-07-27

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT01824771. Inclusion in this directory is not an endorsement.